R

    Rallybio Corp (RLYB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.79
    -0.02 (-0.12%)

    Market Cap: $89.16M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    -10.60%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.44
    Range$-1.44 - $-1.44
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-1.44+0.0%
    60d ago$-1.44+0.0%
    30d ago$-1.44+0.0%
    7d ago$-1.44+0.0%
    Current$-1.44
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.60
    Range$-1.60 - $-1.60
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.60---
    Sep 26EST
    		-$-1.44---
    Jun 26
    Reported Aug 6
    		$-1.09$-1.28+14.84%Beat-395.5%
    Mar 26
    Reported May 13
    		$-1.46$-1.20-21.67%Miss+13.1%
    Dec 25
    Reported Mar 12
    		$-1.52$-0.15-891.52%Miss-708.0%
    Sep 25
    Reported Nov 6
    		$2.88$-1.56+284.62%Beat+238.5%
    Jun 25
    Reported Aug 7
    		$-0.22N/A+88.78%Beat+92.6%
    Mar 25
    Reported May 8
    		$-1.68$-2.28+26.32%Beat+55.3%
    Dec 24
    Reported Mar 13
    		$0.25$-0.30+183.33%Beat+150.0%
    Sep 24
    Reported Nov 7
    		$-2.08$-2.70+22.96%Beat+42.2%
    Jun 24
    Reported Aug 8
    		$-2.96$-2.86-3.50%Miss+19.6%
    Mar 24
    Reported May 9
    		$-3.76$-3.68-2.17%Miss-9.3%
    Dec 23
    Reported Mar 12
    		$-0.50$-0.45-11.11%Miss-8.7%
    Sep 23
    Reported Nov 9
    		$-3.60$-3.98+9.55%Beat+25.0%
    Jun 23
    Reported Aug 8
    		$-3.68$-3.77+2.39%Beat+19.3%
    Mar 23
    Reported May 9
    		$-3.44$-3.72+7.53%Beat+10.4%
    Dec 22
    Reported Mar 6
    		$-0.46$-0.60+23.33%Beat-9.5%
    Sep 22
    Reported Nov 7
    		$-4.80$-4.32-11.11%Miss-62.2%
    Jun 22
    Reported Aug 8
    		$-4.56$-4.88+6.56%Beat-62.9%
    Mar 22
    Reported May 10
    		$-3.84$-3.76-2.13%Miss+6.6%
    Dec 21
    Reported Mar 15
    		$-0.42$-0.39-7.69%Miss+89.8%
    Sep 21
    Reported Nov 10
    		$-2.96N/A+58.19%Beat-50.2%
    Jun 21
    Reported Sep 9
    		$-2.80$-2.80+0.00%Beat-
    Mar 21
    Reported Jun 2
    		$-4.11$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-4.11$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-1.97$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-14.11EV/EBITDA-1.41x
    Price/FCF3.58xFCF Yield27.92%
    Profitability
    Profit Margin7051.00%Operating Margin-3935.00%
    ROE64.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio27.26xQuick Ratio27.26x
    Trading Statistics
    Beta-0.86Avg Volume18.39K
    52-Week High$17.5752-Week Low$3.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.81
    SMA 20$16.66
    SMA 50$16.29
    SMA 200$10.53
    EMA 10$16.78
    EMA 20$16.67
    EMA 50$16.07
    EMA 200$11.80

    MACD

    Line: 0.18Signal: 0.20Hist: -0.02

    ADX

    ADX: 36.5+DI: 17.4-DI: 10.9

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down24.0
    PSAR$17.33

    Bollinger Bands

    Upper Band$17.30
    Lower Band$16.01
    %B Position771%(Upper)
    Band Width0.60

    RSI (14-Day)

    Neutral
    56.2

    Momentum Oscillators

    Stoch %K46.5
    Stoch %D53.0
    Williams %R-54.9
    ROC (10d)-1.2%
    Momentum-0.21
    CCI (20d)25.8
    MFI (14d)70.0

    Volatility Measures

    ATR (14d)$0.47(2.8%)
    StdDev (20d)0.32
    Hist Vol19.4%(Low)

    Volume Flow

    VWAP$16.78
    OBV167.1M
    AD Line14.4B
    CMF (20d)-0.179

    Volume Metrics

    Avg Vol (20d)18.3K
    Vol Ratio0.8x
    VWMA (20d)$16.59

    Pivot Points

    R3$17.73
    R2$17.42
    R1$17.12
    Pivot Point$16.81
    S1$16.51
    S2$16.20
    S3$15.90

    Advanced Oscillators

    TSI16.32
    Ultimate Osc47.3
    KST41.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$212,000$222,000$212,000$212,000$212,000$38,000$299,000$299,000$0$228,000$0
    Cost of Revenue$0$0$3,000$0$0$0$30,000$0$0$0$114,000$0
    Gross Profit$0$212,000$222,000$212,000$212,000$212,000$38,000$299,000$299,000$0$114,000$0
    Operating Expenses$5.65M$8.95M$6.63M$7.14M$10.27M$9.88M$11.65M$12.37M$17.33M$19.79M$21.11M$19.36M
    R&D$758,000$2.87M$3.65M$4.14M$6.07M$5.72M$7.38M$8.24M$12.95M$12.94M$15.92M$13.29M
    SG&A$4.89M$6.07M$2.98M$2.99M$4.20M$4.16M$4.26M$4.13M$4.39M$6.85M$5.19M$6.08M
    Operating Income$-5,653,000$-8,733,000$-6,412,000$-6,925,000$-10,057,000$-9,670,000$-11,608,000$-12,066,000$-17,035,000$-19,787,000$-21,112,000$-19,363,000
    Interest Income$218,000$201,000$560,000$462,000$523,000$644,000$811,000$986,000$1.14M$1.28M$2.01M$1.54M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$44.99M$-8,278,000$-5,852,000$16.02M$-9,416,000$-8,852,000$-10,614,000$-10,829,000$-15,749,000$-18,344,000$-19,629,000$-17,726,000
    Income Tax Expense$1.32M$0$0$0$0$0$0$0$0$0$0$0
    Net Income$43.66M$-8,278,000$-5,852,000$16.02M$-9,703,000$-9,439,000$-11,044,000$-11,466,000$-16,236,000$-19,029,000$-20,242,000$-18,374,000
    EBITDA$44.77M$-8,527,000$-6,506,000$15.48M$-10,066,000$-9,678,000$-11,711,000$-12,124,000$-17,274,000$-20,124,000$-21,851,000$-19,937,000
    EBIT$44.77M$-8,479,000$-6,412,000$15.55M$-9,939,000$-9,496,000$-11,425,000$-11,815,000$-16,892,000$-19,620,000$-21,230,000$-19,271,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RLYB

    News

    Balyasny Asset Management L.P. Exits Rallybio Corp (RLYB) Stake in 13DG Filing

    Balyasny Asset Management L.P. has fully exited its position in Rallybio Corp (RLYB) by selling 376,573 shares at $16 each, a move documented in a 13DG filing with the SEC. Despite Rallybio's recent 193.37% year-to-date surge, the firm's exit suggests concerns over long-term growth and profitability, reflected in Rallybio's low GF Score of 28/100 and operational challenges. The transaction highlights a divergence in investor sentiment, as some gurus still hold the stock, while Balyasny reallocates its capital.

    GuruFocus•8/21/26•
    Somewhat-Bearish

    Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A

    Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 3.56% in Rallybio Corporation's common stock as of June 30, 2026. This stake amounts to 188,422 shares, over which the group holds shared voting and shared dispositive power. The Schedule 13G/A filing indicates that this group holds 5% or less of Rallybio's common stock, classifying them as significant but non-controlling shareholders.

    Stock Titan•8/14/26•
    Neutral

    Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio

    Cormorant Asset Management, LP and Bihua Chen have reported that they no longer beneficially own any shares of Rallybio Corp (RLYB), marking their ownership at 0%. This disclosure, filed as an amendment to a Schedule 13G, indicates zero sole or shared voting or dispositive power over Rallybio's common stock. The 0% ownership is calculated based on 5,298,137 shares of Rallybio common stock outstanding as of May 8, 2026.

    Stock Titan•8/14/26•
    Neutral

    Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

    Balyasny Asset Management L.P. and related entities have filed an amended Schedule 13G/A for Rallybio Corp (RLYB), reporting that they no longer beneficially own any shares. The filing indicates 0 shares owned, representing 0% of the outstanding common stock, and confirms no voting or dispositive power. This update is based on Rallybio's 5,298,137 shares outstanding as of May 8, 2026.

    Stock Titan•8/14/26•
    Neutral

    Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Rallybio Corp (RLYB) has an earnings forecast score of 6.00, placing it 330 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.00 for RLYB, with recent EPS at -$1.03 against an expectation of -$1.46. Based on one analyst's rating, the stock currently holds a "Hold" trend.

    TradingKey•8/7/26•
    Neutral

    Frequently Asked Questions About RLYB

    Does RLYB pay dividends?
    Rallybio Corp (RLYB) does not currently pay a regular dividend.
    What is RLYB's market cap?
    Rallybio Corp (RLYB) has a market capitalization of $89.16M with a current stock price of $16.79.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In